Eisai's lenvatinib shows significant improvement in progression-free survival in some cancers

8 September 2014

Results from a Phase III study of Japanese drug major Eisai’s (TYO: 4523) cancer therapy lenvatinib have shown a significant improvement in progression-free survival in radioiodine-refractory differentiated thyroid cancer.

Analyses of subgroups showed that in people with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC) showed progression-free survival in lenvatinib stood at 18.3 months on average, compared to 3.6 months in placebo.

The study was a multicenter, randomized, double-blind, placebo-controlled Phase III trial to compare the PFS of people with RR-DTC and radiographic evidence of disease progression within the prior 13 months, treated with once-daily, oral lenvatinib (24mg) versus placebo. Lenvatinib is an oral multiple tyrosine kinase inhibitor with a binding mode that selectively inhibits the kinase activities of all vascular endothelial growth factor receptors.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK